1. Home
  2. BEAM vs RXST Comparison

BEAM vs RXST Comparison

Compare BEAM & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$25.64

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Logo RxSight Inc.

RXST

RxSight Inc.

N/A

Current Price

$12.62

Market Cap

513.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
RXST
Founded
2017
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
513.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
BEAM
RXST
Price
$25.64
$12.62
Analyst Decision
Strong Buy
Hold
Analyst Count
12
11
Target Price
$48.09
$11.30
AVG Volume (30 Days)
1.9M
842.9K
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$55,701,000.00
$142,085,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$26.52
$4.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.75
52 Week Low
$13.53
$6.32
52 Week High
$35.25
$39.37

Technical Indicators

Market Signals
Indicator
BEAM
RXST
Relative Strength Index (RSI) 50.81 65.75
Support Level $25.86 $12.07
Resistance Level $28.10 $13.22
Average True Range (ATR) 1.66 0.64
MACD 0.03 -0.01
Stochastic Oscillator 39.97 68.81

Price Performance

Historical Comparison
BEAM
RXST

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About RXST RxSight Inc.

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Share on Social Networks: